Weller, David
Filli, Linard
Meyer, Christian
Lörincz, Lilla
Linnebank, Michael
Weller, Michael
Curt, Armin
Zörner, Björn http://orcid.org/0000-0003-2246-3359
Funding for this research was provided by:
Betty and David Koetser Foundation
Clinical Research Priority Program (CRPP) “NeuroRehab” of the University of Zurich
Swiss MS Society
Biogen
Article History
Received: 7 May 2020
Revised: 28 May 2020
Accepted: 30 May 2020
First Online: 4 June 2020
Compliance with ethical standards
:
: CM received a travel grant from Biogen. ML received grants, honoraria or funding from Almirall, Bayer, Biogen, Genzyme, Merck, Novartis, Roche and Teva. MW received research grants from Abbvie, Adastra, Bristol Meyer Squibb (BMS), Dracen, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, Piqur and Roche, and honoraria for lectures or advisory board participation or consulting from Abbvie, Basilea, Bristol Meyer Squibb (BMS), Celgene, Merck, Sharp and Dohme (MSD), Merck (EMD), Novocure, Orbus, Roche and Tocagen. BZ received honoraria, travel grants, and funding from Biogen and Roche. The other authors declare that there is no conflict of interest.
: The studies were approved by the Zurich cantonal ethics committee (KEK-2011-0445, KEK-2014-0004) in Switzerland.
: All participants gave written, informed consent.
: All authors read and approved the final manuscript and gave consent for publication.